1. Home
  2. IAUX vs NTLA Comparison

IAUX vs NTLA Comparison

Compare IAUX & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo i-80 Gold Corp.

IAUX

i-80 Gold Corp.

HOLD

Current Price

$1.44

Market Cap

1.3B

Sector

N/A

ML Signal

HOLD

Logo Intellia Therapeutics Inc.

NTLA

Intellia Therapeutics Inc.

HOLD

Current Price

$13.00

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IAUX
NTLA
Founded
2020
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.8B
IPO Year
2021
2016

Fundamental Metrics

Financial Performance
Metric
IAUX
NTLA
Price
$1.44
$13.00
Analyst Decision
Buy
Buy
Analyst Count
1
23
Target Price
$1.50
$20.02
AVG Volume (30 Days)
9.7M
5.4M
Earning Date
05-12-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
11.76
27.43
EPS
N/A
N/A
Revenue
$95,193,000.00
$67,671,000.00
Revenue This Year
$132.25
N/A
Revenue Next Year
$89.76
$62.75
P/E Ratio
N/A
N/A
Revenue Growth
89.12
16.92
52 Week Low
$0.55
$7.95
52 Week High
$2.24
$28.24

Technical Indicators

Market Signals
Indicator
IAUX
NTLA
Relative Strength Index (RSI) 40.85 47.60
Support Level $0.92 $11.71
Resistance Level $1.65 $14.02
Average True Range (ATR) 0.08 1.02
MACD -0.00 0.09
Stochastic Oscillator 6.52 33.78

Price Performance

Historical Comparison
IAUX
NTLA

About IAUX i-80 Gold Corp.

i-80 Gold Corp is a well-financed gold and silver producer engaged in the exploration, development, and production of gold, silver, and poly-metallic deposits. The Company's principal assets include the Ruby Hill Mine, Lone Tree Mine, Granite Creek Mine, and McCoy-Cove Project.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: